PLSE Oppenheimer analyst Suraj Kalia raised the firm's price target on Pulse Biosciences to $35 from $30 and keeps an Outperform rating on t
PLSE Oppenheimer analyst Suraj Kalia raised the firm's price target on Pulse Biosciences to $35 from $30 and keeps an Outperform rating on the shares. Preliminary evidence suggests nsPFA has a better safety and efficacy profile vs. traditional microsecond PFA and radiofrequency, though this has to be validated in pivot